Clinical Research Chatter

Type 2 Diabetes or Heart Disease? Overweight? We may have a clinical research study for you.

noreply@blogger.com (Sara Rowe) — Thu, 24 May 2012 20:57:00 +0000

We are currently conducting a research study of an investigational medication designed for weight loss. The purpose of the research study is to evaluate the investigational medication for weight loss in patients with heart disease and/or type 2 diabetes. The trial could last up to 4 years and consists of up to 14 office visits (including screening visit).

If you:

- Are a man at least 45 years of age or a woman at least 50 years of age

AND

- Have Type 2 Diabetes AND high blood pressure or high cholesterol for which you are taking medication or you smoke

AND/OR

- Have a history of heart disease, such as a heart attack, angina, coronary artery bypass graft (CABG) surgery, stent placement or angioplasty

You may be interested in learning more about this research study. Study participants will receive study medication, study-related care and as well as participate in a weight management program. All study-related care is provided at no cost. Financial compensation up to $40.00 per study visit is provided for time and travel.

Learn more now at http://www.pmgweightlossstudy.com/

May is Asthma Awareness Month

noreply@blogger.com (Allison Kelly) — Mon, 07 May 2012 17:41:00 +0000

If you're a person living with asthma, a friend, family member, co-worker or health care professional, take a moment to learn more about asthma by viewing an educational video from the American Lung Association.

Asthma is a chronic lung disease that makes it harder to move air in and out of your lungs. There is no cure for asthma; however, it can be managed so you can live a normal, healthy life. Asthma causes airways in your lungs to become inflamed which makes them extra sensitive to things you're exposed to in the environment such as dust, smoke, pet dander and other allergens. Asthma can also be triggered by illnesses like the common cold or flu. When someone with asthma is exposed to a trigger, the insides of the airways make extra mucus and swell even more making breathing even harder. This is referred to as an asthma attack.

The exact cause of asthma is unknown but is influenced by family history, allergies, respiratory infections during childhood and environmental factors like irritants and pollution.

PRESS RELEASE

noreply@blogger.com (Allison Kelly) — Fri, 03 Feb 2012 18:49:00 +0000

FOR IMMEDIATE RELEASE

PMG RESEARCH OF WILMINGTON AND PMG RESEARCH OF WINSTON-SALEM: THE FIRST MEDICAL CENTERS IN NORTH CAROLINA TO IMPLANT INVESTIGATIONAL DEVICE TO TREAT OBSTRUCTIVE SLEEP APNEA

Winston-Salem, NC, Friday, February 3, 2012 – Two sites in the PMG Research network, PMG Research of Wilmington and PMG Research of Winston-Salem, implanted the Apnex® Hypoglossal Nerve Stimulation (HGNS®) System in a patient to treat obstructive sleep apnea (OSA), becoming the first medical centers in North Carolina to perform this procedure. The patients are participating in a FDA-approved clinical study. The study is sponsored by Apnex Medical, Inc.

“The Apnex HGNS System is anticipated to significantly reduce the number of times a person’s breathing is interrupted each night, in people that suffer from OSA. This new treatment offers hope to people who have not been successfully treated with continuous positive airway pressure (CPAP) devices" says Douglas Lee, MD, from Wilmington Health and lead clinical trial investigator for PMG Research of Wilmington. "We are excited to be part of this important study”, explained Jason Thomason, MD, from Salem Chest Specialists and lead clinical trial investigator at PMG Research of Winston-Salem.

ABOUT OBSTRUCTIVE SLEEP APNEA

According to the World Health Organization, approximately 100 million people worldwide have OSA. In the United States, symptomatic OSA affects 1 in 4 men and 1 in 9 women. It most often occurs when the airway muscles fail to keep the airway open during sleep. Untreated OSA increases the risk of death; as well as stroke, high blood pressure, coronary artery disease, heart failure and diabetes. It causes fragmented sleep which leads to excessive daytime sleepiness, resulting in an increased risk of accidents and lost productivity. Current OSA treatments are not always successful or well tolerated.

ABOUT THE APNEX HGNS SYSTEM

The Apnex HGNS System is an implanted medical device that activates muscles of the upper airway to ensure that the airway remains open during sleep. During sleep the system monitors the patient’s breathing and delivers mild stimulation to the hypoglossal nerve, the nerve that controls the tongue. As the nerve is stimulated, the tongue gently moves forward to keep the airway open. The stimulation is timed to a patient’s own breathing pattern. The device automatically turns on when the patient is sleeping, and turns off when the patient is awake.

ABOUT THE APNEX CLINICAL STUDY

The purpose of the Apnex Clinical Study is to determine whether the Apnex HGNS System is a safe and effective treatment for OSA in patients who have not received lasting benefit from CPAP or other OSA treatments. The study is being performed by sleep specialists at clinical study centers throughout the U.S. and Australia.

The Apnex Clinical Study is now enrolling patients. People who are interested in learning if they might qualify for the study can call 1-888-975-3370 or go to http://www.sleepapneatrial.com/.

Caution: The Apnex HGNS System is an investigational device and is limited by Federal (or United States) law to investigational use only.

ABOUT PMG RESEARCH

PMG Research, Inc. is an Integrated Site Network based in Winston-Salem, NC. The staff and physicians at PMG Research have contributed to the development of numerous medications, medical devices and vaccines. PMG’s mission is to provide unparalleled service to their clinical trial participants and pharmaceutical sponsors. Visit PMG Research at http://www.pmg-research.com/.

Diabetes Medication Widely Studied in PMG Network Receives FDA Approval!

noreply@blogger.com (Allison Kelly) — Mon, 30 Jan 2012 14:47:00 +0000

BYDUREON (exenatide extended release for injectable suspension) just received FDA approval. Special thanks to all of the participants in these clinical trials as well as every PMG site!

BYDUREON is the first and only treatment for adults with Type 2 Diabetes that delivers continuous glycemic control in a single weekly dose. Learn more about BYDUREON HERE...

Birth Control Patch Studied at PMG Ready for FDA Review

noreply@blogger.com (Allison Kelly) — Wed, 11 Jan 2012 14:26:00 +0000

Agile Therapeutics announced that clinical trials are complete for their combination hormonal contraceptive patch and the product is ready for FDA review in 2012. We will keep you posted on the progress of approval of the patch. Thanks to all of the participants, PMG sites, and staff that contributed to this major milestone for Agile's low-dose birth control patch. Read more about Agile's news here.

Sarah Call Gives Back to Wake Med and the MS Society

noreply@blogger.com (Allison Kelly) — Wed, 04 Jan 2012 14:51:00 +0000

Sarah Call, Clinical Research Coordinator at PMG Research of Raleigh, showed her holiday spirit and put her Best Foot Forward by stepping up to fill in for the flautist who called in sick at the last minute for the Wake Med Hospital Holiday Music Concert. The group was led by Sheila DeBastiani, a friend of PMG, who is involved with Wake Med's Clinical Trials Department. Ira David Wood, III, Executive Director of Theatre in the Park in Raleigh, spoke at the event. Check out Sarah in the video above!

Sarah volunteered her time with the Eastern North Carolina Multiple Sclerosis National Chapter this year. Sarah shared her story of service with me and wanted to share it with you....

"My aunt has Multiple Sclerosis and I have volunteered for the past two years with the MS Scholarship Committee for the Eastern North Carolina MS National Chapter. For my community service day in 2011, I spent the day at the Chapter helping to complete patient surveys. The Eastern NC chapter has a unique program that individuals across the Eastern Carolinas can apply for financial aid for food, rent, utilities, and necessities. My role was to call anyone who had received financial aid and poll them on customer service and how user friendly the financial aid service was, and if the financial aid was able to alleviate their temporary financial troubles. The surveys had to be completed by the end of the year, and the MS Chapter had just lost their intern, so they definately needed the extra hand! One man that I spoke with, who's in a nursing home, was able to use the service to repair his wheelchair. The MS Chapter helped one woman from losing her home and another to buy clothes for her children for school. I learned that people are so grateful for even the smallest amount. Everyone I spoke to was so grateful. It was exciting to see another corporation using the 'Best Foot Forward' policies and then going back to ensure that their customer service was up to par. Thank you for the opportunity to spend a day at the National MS Chapter!"

Great job Sarah on contributing your time and talents, and putting your Best Foot Forward to such a great cause!

PMG of Winston-Salem's TC Deluca Gives Back

noreply@blogger.com (Allison Kelly) — Tue, 03 Jan 2012 14:43:00 +0000

TC Deluca, a Senior Clinical Research Coordinator in Winston-Salem, used her community service day this year volunteering with the Challenger Division of Little League. Here is TC's story of service.....

"I used my service day to go to Williamsport, PA with my husband to volunteer at the Challenger Division Championship Game in August. The Challenger Division of Little League is designed to offer the opportunity to play Little League baseball to players who are physically and mentally disabled. My husband and I run the Challenger Division League at SW Forsyth Little League in Clemmons, NC and have done so for the last 5 years. We have approximately 50 kids who come to play ball ever Saturday during the Spring Season. Our kids range in age from 3-22 and represent a variety of special needs including Autism, Down's Syndrome, and Cerebral Palsy. We have quite a few players who are confined to wheelchairs so must use a walker to get around the bases. The reason we went to Williamsport this year is that our team has been invited to play in the Little League World Series in Williamsport in 2012!"

Great work TC!!! Learn more about the Challenger Division of Little League here.

Sara Rowe Gives Back to her Local Community through Habitat for Humanity

noreply@blogger.com (Allison Kelly) — Fri, 30 Dec 2011 13:23:00 +0000

Sara Rowe, PMG's Outreach and Facilities Coordinator, gave back to her local community, High Point, NC through Habitat for Humanity. Here is Sara's story of service.....

"I participated in a Women's Build with Habitat for Humanity. My mom volunteers at the High Point Habitat 3 days a week and asked if I would like to participate. Habitat is currently partnering with the City of High Point to develop new homes near Washington Terrace Park. This exciting new development brings together the vision of the city's Core Plan with the need for affordable housing in the High Point community. What I learned that day is that a homeowner has to have the ability to pay a 25-year interest-free mortgage, have acceptable credit history and reasonable debt load, have a steady form of income and be a US citizen or a legal immigrant. They also have to be willing to partner with Habitat by investing 250 hours per adult in sweat equity and attending educational classes.

The house we worked on during the Women's Build had a foundation and the frame of the house when we arrived. They had just started on this home a few weeks before. Some of the group worked on the roof and I got to help with installing the subfloor.... what a job! We carried, placed and nailed wood most of the day. We had a blast and I found out that I can't hammer that well! Hammering is not my thing, but it was certainly a great feeling knowing I was building a home for someone who really needs it. The new owner helped us that morning.... she was extremely humble and appreciative. It was a wonderful experience and I plan to volunteer again soon. They need it and I truly believe in what Habitat does for the community."

Well done Sara!!! Learn more about Habitat for Humanity in High Point, NC.

PMG's Alissa Wulf Gives Back to her Alma Mater

noreply@blogger.com (Allison Kelly) — Thu, 29 Dec 2011 14:03:00 +0000

Alissa Wulf, one of PMG Research's Senior Clinical Research Coordinators in Charleston, SC, used her community service day this year to give back to her Alma Mater, Coastal Carolina University (CCU) and the Women's Soccer Program. During the early spring of 2011, Alissa worked closely with two other fellow alumni, the current coaching staff at CCU, and the university's athletic department to help organize and coordinate the first ever CCU Men's and Women's Soccer Joint Alumni Weekend.

In addition to the typical work associated with planning such a large event, Alissa's main objective was to find a way to honor and remember a close friend and former teammate, April Stirton, who was tragically killed in an accident in April 2010. Alissa had reached out to CCU's Athletic Director, the Chanticleer Athletic Foundation, and the President of the University to see what was possible. After numerous brainstorms, emails, phone calls and the final approval of the President of the university, they were able to retire April's #26 from the women's soccer program and establish a memorial fund in her honor, with all the proceeds going to the CCU women's soccer program in her name. April's family was in attendance for the ceremony, and together friends, teammates and family celebrated her life. Alissa is looking forward to working on the event again in 2012. See the press release for the event here.

As a result of Alissa's service to her Alma Mater, she was asked to represent the women's soccer program as an Association Officer for the Coastal Carolina Letterwinners Association. The mission of the association is to enhance the tradition and values of Coastal Carolina University by encouraging CCU Athletic Letterwinners to be lifelong members of the Coastal Carolina Athletics family. The focus is on alumni camaraderie, athletic excellence, career development and service.

Way to go Alissa!!!

FDA Approves High Blood Pressure Medication Studied in PMG Network!

noreply@blogger.com (Allison Kelly) — Wed, 28 Dec 2011 17:09:00 +0000

The FDA has approved Edarbyclor (azilsartan medoxomil and chlorthalidone) for the treatment of high blood pressure in adults. Congratulations to all of the participants that contributed to the development of a new high blood pressure combination medication through their participation in Takeda clinical trials with PMG! Thanks to all of the PMG sites that worked so hard on the Edarbyclor projects as well! To learn more about Edarbyclor, please click here.

Giving Back Extends into the Holidays

noreply@blogger.com (Allison Kelly) — Fri, 16 Dec 2011 15:00:00 +0000

Giving back is part of the PMG way of life. Every holiday season, our staff gears up to give back to our local communities and lend a helping hand to those in need. The entire year of 2011 has represented a record year of giving at PMG:

Every staff member this year was given a day of service - a day to give back to their local community in whatever way inspires them. That's nearly 4 full months of community service!
Not only did our staff give back, our study participants joined us in the spirit of giving. For every individual that participates in a clinical trial with PMG, a vaccine is donated to a child in need through the Greater Gift Initiative as a way to thank and honor them for their participation. In the last year, on behalf of our participants, we've donated nearly 12,000 vaccines for polio, diptheria, pertussis, tetanus, Hib and hepatitis to children in need around the world.

Stay tuned to our blog and Facebook page throughout the holiday season and make sure to share your story of giving back too!

The Power of Clinical Trial Participation

noreply@blogger.com (Allison Kelly) — Thu, 08 Dec 2011 17:57:00 +0000

Carroll Paxton, a PMG Research of Bristol participant, shares his story on dLifeTV about participating in a clinical trial for Type 2 Diabetes with Dr. Stephanie Powell. This is a great story that will open your eyes about insulin use in Type 2 Diabetes!

Find Carroll's story here.

PMG Sleep Apnea Study Highlighted in Winston-Salem Journal and WFMY News

noreply@blogger.com (Allison Kelly) — Wed, 16 Nov 2011 19:39:00 +0000

PMG Research of Winston-Salem was recently featured in the Business Briefcase in the Winston-Salem Journal, as well as on the WFMY News website. Our Winston-Salem and Wilmington offices are the first medical centers to start a study on Apnex Medical's Hypoglossal Nerve Stimulation (HGNS) system, which is an implantable device to treat obstructive sleep apnea (OSA).

The HGNS system provides a novel approach to treating OSA. The implanted medical device activates muscles of the upper airway to ensure that the airway remains open during sleep. The system monitors breathing during sleep and delivers mild stimulation to the hypoglossal nerve, which controls the tongue. As the nerve is stimulated, the tongue gently moves forward to keep the airway open.

In the United States, symptomatic OSA affects 1 in 4 men and 1 in 9 women. Worldwide, approximately 100 millon people have OSA.

For more information about this trial please visit http://www.sleepapneatrial.com/ or call 1-888-975-3370.

PMG Research of Wilmington Participates in Heart Walk

noreply@blogger.com (Allison Kelly) — Fri, 21 Oct 2011 13:03:00 +0000

Last weekend, the staff of PMG Research of Wilmington participated in the Start! Heart Walk sponsored by the American Heart Association. There are nearly 350 Start! Heart Walks across the country, all raising money to fight against the country's #1 and #3 killers, heart disease and stroke.

Way to go PMG Research of Wilmington in your efforts to raise awareness of heart disease and stroke, encourage healthier lifestyles and help in funding groundbreaking research and life-saving programs sponsored by the American Heart Association.

PMG Research, Inc. has been a very strong supporter of the mission of the American Heart Association and Start! Heart Walks over the years in both Winston-Salem and Wilmington, NC.

Michael J. Fox Urges Americans to Participate in Research Trials

noreply@blogger.com (Allison Kelly) — Fri, 17 Jun 2011 17:25:00 +0000

Michael J. Fox says "Scientific progress starts with us." He urges Americans to participate in clinical trials in a recent article written in the San Francisco Chronicle. "Today, America is waiting expectantly for a new generation of scientific breakthroughs- in cancer, AIDS, Alzheimer's disease, and of course, Parkinson's disease. Yet we've lost sight of a critical element of any success - own own active engagement in the process" Fox says. "Across all diseases, according to 2003-2004 research at the National Institutes of Health, 85 percent of clinical trials finish late because of trouble recruiting volunteers." Meanwhile, almost "a third of trials fail to recruit a single subject and cannot ever begin." He says that everyone can help to find cures for diseases "by donating, volunteering or participating in a trial."

Read the full piece written by Michael J. Fox in the San Francisco Chronicle.

Keeping You in the Loop: Trial Updates

noreply@blogger.com (Allison Kelly) — Thu, 12 May 2011 18:08:00 +0000

Drug Approvals:

Congratulations to all of the participants and sites that contributed to these treatments gaining approval!

FDA approves new flu shot using tiny needle for adults 18-64 years of age. Fluzone intradermal vaccine was studied across the PMG network. Read more.

FDA approves new type 2 diabetes treatment, Trajenta (linagliptin), which has been studied widely across the PMG network of sites. Learn more.

Clinical Trial Results:

Thank you to all of the participants and sites that contributed to these advancements in medicine!

Pneumonia vaccine studied across PMG network shown effective in adults over 50. Read more.

Clinical trial results for triglyceride drug studied PMG Research of Charleston, Hickory, Raleigh and Winston-Salem show significant reductions in triglyceride levels in patients that participated. Read more.

Positive results from Meniere's Disease drug studied at PMG Research of Salisbury, Winston-Salem and Wilmington- novel treatment is well-tolerated and demonstrates improvement in debiliating symptoms of severe inner ear disorder. Learn more.

Cholesterol medication studied at PMG Research of Raleigh demonstrates a lowering of LDL-C (bad cholesterol). Read more.

Announcing: PMG Research of Knoxville!

noreply@blogger.com (Allison Kelly) — Mon, 02 May 2011 13:04:00 +0000

PMG is proud to announce the opening of our 11th clinical research site, PMG Research of Knoxville, through a partnership with Summit Medical Group. Summit is the largest provider of primary care in the East Tennessee region with over 220 physicians and 50 office locations. The research site will operate out of Summit's Norwood Family Practice office. PMG Research of Knoxville will be working with Drs. Paul Wakefield, John Swisher and Lynn Nichols, all of whom function as Principal Investigators at the site. Un Han Kim, a PMG study coordinator from PMG of Salisbury, has relocated to Knoxville to lead and faciliate the upstart of the site.

Here we grow again! Welcome PMG Research of Knoxville and Summit Medical Group to the PMG Family.

Share Your Memories About Dr. Littlejohn

noreply@blogger.com (Allison Kelly) — Fri, 01 Apr 2011 12:53:00 +0000

We invite you to share your fond memories of Dr. Littlejohn.

Trial Updates

noreply@blogger.com (Allison Kelly) — Fri, 25 Mar 2011 13:36:00 +0000

Drug Approval News:

You have helped move medicine forward!!!

The FDA has approved the Shingles Vaccine (Zostavax) for patients 50 and older! This vaccine is already approved for patients 60 and older. The PMG Research network has done multiple trials with Zostavax and would like to thank all of the participants and sites that helped to conduct the research for Zostavax to allow it to be approved for a younger age group. For more information about this report, click here.

The FDA also approved Takeda's drug Edarbi to treat high blood pressure. The FDA concluded that "the newly approved agent was more effective in clinical studies than two other FDA-approved ARB's, valsartan (Diovan) and olmesartan (Benicar)." PMG Research would like to thank all of the volunteers and PMG sites that participated in the trials that helped get this important drug approved. Learn more about Edarbi for high blood pressure here.

Other trial news:

The FDA has granted fast track designation to Furiex' drug for Irritable Bowel Syndrome. Fast track designation allows the development and approval process to be expedited for drugs that are intended to treat serious or life-threatening conditions or address unmet medical needs. Several PMG sites are currently involved in trials for this IBS drug, MuDelta. Furiex Chief Medical Officer says "We believe we are making significant progress with the Phase II trial, and this designation allows us to potentially get MuDelta to market faster." Learn more about MuDelta.

BioSante reports positive results for treatment to treat low libido in post-menopausal women. BioSante hopes this medication will become the first treatment to boost sex drive in post-menopausal women. PMG Research is currently involved in conducting trials for the development of LibiGel. Learn more about the trial results for LibiGel here.

Auxilium Pharmaceuticals announced that enrollment has been met in the Xiaflex Phase III program for Peyronie's Disease. PMG Research has contributed to enrollment in Xiaflex development program. Auxilium says that enrollment of these patients so quickly indicates "enthusiasm in the urology community and their prospective patients for a non-surgical treatment alternative." Learn more about Xiaflex.

Greater Gift Initiative Featured in the Winston-Salem Journal

noreply@blogger.com (Allison Kelly) — Mon, 21 Feb 2011 20:05:00 +0000

PMG Research and The Greater Gift Initiative were featured in the business section of this past Sunday's Winston-Salem Journal. Richard Craver, a reporter with the Winston Salem Journal interviewed Jennifer Byrne, PMG Research's CEO, about the birth of the Greater Gift concept and what we hope to acheive with the launch of the Greater Gift Initiative. Dr. Holmes, a PMG Investigator, as well as Annette Scippio, a PMG clinical trial participant, were also interviewed by Mr. Craver. Don't miss the full article.

The Greater Gift Initiative Is Here!

noreply@blogger.com (Allison Kelly) — Mon, 31 Jan 2011 16:03:00 +0000

We have launched the Greater Gift Initiative (GGI)! The mission of the Greater Gift Initiative is to advance global health and highlight the greater good of clinical trial participation by gifting a vaccine to a child in honor of every clinical trial volunteer. After months of planning the GGI is being rolled out in honor of the clinical trial volunteers who make the advancement of medicine possible. The GGI has big plans for the next year, beginning with the launch of our website last Thursday.

First, we are honoring the 2010 clinical trial volunteers who participated with PMG Research by donating an oral polio vaccine in conjunction with the Rotary International PolioPlus Program. The funds donated will help in covering the costs of the vaccines, and will also help defray costs associated with transportation, refrigeration, training, administration, social mobilization, and reporting to the World Health Organization. The polio vaccines will be administered in India, Afghanistan, Pakistan, or Nigeria, four countries where the disease is still endemic. Each clinical trial participant will be notified by email or postcard about their important involvement in the success of the PolioPlus Program.

Beginning in 2011, the Greater Gift Initiative will be partnering with GAVI (Global Alliance for Vaccines and Immunizations) for the delivery of the pentavalent vaccine (Pertussis, Diphtheria, HiB, Tetanus, and Hepatitis B) to 80 of the poorest countries in the world. In 2011, PMG Research participants will receive certificates by mail notifying them of this gift made in their honor.

Our ultimate goal at the Greater Gift Initiative is to have all pharmaceutical companies, Contract Research Organizations, site management organizations, independent sites, and independent Principal Investigators participate in the donation of vaccines every time a patient volunteer completes a research trial. In 2006, 1.63 million people participated in industry-sponsored clinical research in the United States. Think of the impact on world health if we could donate, in honor of each of these participants, a life-saving vaccine to a child at risk. Every year, 2.4 million children under the age of 5 die from vaccine-preventable diseases and 24 million children worldwide are unvaccinated. The pharmaceutical and clinical trials industries rely on volunteers to participate in the development process of their new products. With the start of the Greater Gift Initiative, volunteers participating in clinical research advance medical science not only in the U.S., but across the globe. At the core of the Greater Gift Initiative, we are about "Volunteers Advancing Health." Visit the Greater Gift Initiative at http://www.greatergiftinitiative.org/ and sign up for our e-newsletter.

Congratulations to Dr. Littlejohn!

noreply@blogger.com (Allison Kelly) — Mon, 17 Jan 2011 14:53:00 +0000

Congratulations to our President and Executive Medical Director, Dr. Thomas W. Littlejohn, III, on his recent election to the Board of Trustees of the Academy of Pharmaceutical Physicians and Investigators (APPI) and the Association of Clinical Research Professionals (ACRP). APPI's mission is to promote and advance excellence and professionalism in pharmaceutical medicine and clinical research. We're excited about this new opportunity for Dr. Littlejohn and the PMG Research integrated site network!

HERE WE GROW AGAIN!

noreply@blogger.com (Allison Kelly) — Wed, 29 Dec 2010 21:45:00 +0000

Happy New Year! We are pleased to announced that as of January 1, 2011 the PMG Research network of sites has changed names. The new naming convention outwardly displays that each site is a part of PMG Research operating in a specific city and continues to visually promote the company goal of integration, as well as allow for continued site expansion. This is a change in name only and you can expect to receive the excellent service you have come to expect from our staff. If you have any questions about the change, please do not hesitate to contact us at contactus@pmg-research.com.

The new site names are as follows (along with their previous name):

PMG Research of Bristol
     (formerly TriCities Medical Research)
PMG Research of Cary
     (formerly Cary Medical Research)
PMG Research of Charleston
     (formerly Palmetto Medical Research)
PMG Research of Charlotte
     (formerly Metrolina Medical Research)
PMG Research of Hickory
     (formerly Unifour Medical Research)
PMG Research of Johnson City
     (formerly East Tennessee Medical Research)
PMG Research of Raleigh
     (formerly Triangle Medical Research)
PMG Research of Salisbury
     (formerly Crescent Medical Research)
PMG Research of Winston-Salem
     (formerly Piedmont Medical Research)
PMG Research of Wilmington
     (formerly New Hanover Medical Research and Wilmington Medical Research)

You will continue to see progress within the PMG Network as 2011 moves forward and we will certainly keep you in the loop with new developments.   We strive to always put our Best Foot Forward for you and we thank you immensely for your support of the PMG Research Integrated Site Network.  Here's to a Happy and Healthy 2011!

Keeping You in the Loop: Triglyceride Trial Follow Up

noreply@blogger.com (Allison Kelly) — Mon, 06 Dec 2010 21:20:00 +0000

Amarin Pharmaceutical's Omega-3 medication that was studied in the PMG network this year was found to lower triglyceride levels by 45% in study participants.

Triglycerides are a type of fat that can lead to heart disease when found in high levels in the blood. More than 3.8 million people in the US have high triglyceride levels. Similar medications have been found to raise bad cholesterol, or LDL, by as much as 40-50%, but Amarin's medication did not cause an increase in bad cholesterol. Amarin hopes to submit it's triglyceride medication to the FDA for review sometime next year. Thank you to all of the volunteers that participated in these trials with us in Mt. Pleasant, Winston-Salem, Raleigh and Hickory!

Read more...

Palmetto Medical Research Community Outreach

noreply@blogger.com (Allison Kelly) — Mon, 22 Nov 2010 20:08:00 +0000

Alissa Wulf and Erin Driscoll help set up the Palmetto Medical Research booth.

The staff of Palmetto Medical Research participated in the 10th Annual Community Health Day in Charleston, SC on Saturday, November 6th to promote the benefits of clinical trial participation and to share the difference that participants make to medical advancement. The event was sponsored by the Franklin C. Fetter Family Health Center and the the Charleston Diabetes Coalition.